Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy.

Eyes with CSC treated with IVBI and achieving complete resolution of subretinal fluid have 50% chance of recurrence in the long term. Thinner choroid and serous pigment epithelial detachment appear protective for recurrences.